Cognitive impairment and p‐tau217 are high in a vascular patient cohort
Authors:
Open Access
- 7 August 2025
- journal article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (8) , e70565
Abstract
INTRODUCTION: Vascular comorbidities are modifiable contributors to cognitive impairment and Alzheimer's disease (AD), yet brain health outcomes are rarely evaluated in cardiovascular patients.METHODS: This study prospectively evaluated cognition and AD pathology in 162 community‐dwelling adults with asymptomatic cardiovascular disease who did not have a clinical diagnosis of dementia or cognitive impairment.RESULTS: Twenty‐nine percent of the cohort had Montreal Cognitive Assessment (MoCA) scores indicative of cognitive impairment or dementia after adjusting for age, sex, and education based on National Alzheimer's Coordinating Center normative data. AD blood biomarker phosphorylated tau217 was elevated in 55% of the cohort, significantly associated with decreased MoCA scores (β = −1.46, 95% confidence interval [CI] −2.53 to −0.39, p < 0.01), and accurately differentiated cognitive impairment (area under the curve 0.94, 95% CI 0.88–0.99).DISCUSSION: This level of undiagnosed cognitive impairment and AD pathology exceeds what would be expected in the general population and highlights a potential need for screening and future work to better identify treatment options.Highlights: Brain health outcomes are rarely evaluated in vascular patients. One hundred sixty‐two adults with asymptomatic cardiovascular disease but without diagnoses of cognitive impairment or dementia were evaluated. Phosphorylated tau217 accurately differentiated cognitive impairment in patients with cardiovascular disease. High levels of cognitive impairment and Alzheimer's disease pathology are greatly underdiagnosed in the cardiovascular population.Keywords
Funding Information
- National Institute on Aging (R01AG070987)
- National Heart, Lung, and Blood Institute (R01 HL159200)
- Arizona Alzheimer's Consortium
- Arizona Biomedical Research Commission (CTR056039, CTR056056)
- Health Sciences, University of Arizona
- Doris Duke Charitable Foundation
This publication has 55 references indexed in Scilit:
- 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive SummaryCirculation, 2011
- Prevalence of Asymptomatic Carotid Artery Stenosis in the General PopulationStroke, 2010
- Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF StudiesJournal of Clinical Neurology, 2009
- Epidemiology, classification, and modifiable risk factors of peripheral arterial diseaseVascular Health and Risk Management, 2007
- Midlife cardiovascular risk factors and risk of dementia in late lifeNeurology, 2005
- Rosuvastatin in the Primary Prevention of Cardiovascular Disease Among Patients With Low Levels of Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive ProteinCirculation, 2003
- Apolipoprotein E ε4 Allele, Elevated Midlife Total Cholesterol Level, and High Midlife Systolic Blood Pressure Are Independent Risk Factors for Late-Life Alzheimer DiseaseAnnals of Internal Medicine, 2002
- Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based studyBMJ, 2001
- Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a ‘thrifty’ allele?Annals of Human Genetics, 1999
- The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes.Diabetes Care, 1999